Anixa Biosciences (NASDAQ:ANIX) Posts Earnings Results

Anixa Biosciences (NASDAQ:ANIX) announced its earnings results on Wednesday. The company reported ($0.08) EPS for the quarter, meeting analysts’ consensus estimates of ($0.08), FiscalAI reports.

Anixa Biosciences Stock Down 2.4%

Shares of ANIX traded down $0.07 during midday trading on Wednesday, reaching $2.83. The company had a trading volume of 459,265 shares, compared to its average volume of 192,694. Anixa Biosciences has a 1-year low of $2.32 and a 1-year high of $5.46. The stock has a market cap of $96.29 million, a PE ratio of -9.13 and a beta of 0.51. The firm has a 50 day simple moving average of $3.36 and a 200-day simple moving average of $2.99.

Insider Buying and Selling at Anixa Biosciences

In other news, CEO Amit Kumar purchased 21,000 shares of the stock in a transaction dated Friday, June 12th. The shares were purchased at an average price of $2.50 per share, with a total value of $52,500.00. Following the transaction, the chief executive officer owned 630,812 shares in the company, valued at $1,577,030. The trade was a 3.44% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last 90 days, insiders have bought 50,024 shares of company stock worth $148,971. Insiders own 26.40% of the company’s stock.

Institutional Investors Weigh In On Anixa Biosciences

Several hedge funds and other institutional investors have recently bought and sold shares of ANIX. Bank of America Corp DE raised its stake in Anixa Biosciences by 1.7% during the third quarter. Bank of America Corp DE now owns 213,955 shares of the company’s stock worth $706,000 after purchasing an additional 3,645 shares during the period. Prosperity Wealth Management Inc. increased its holdings in shares of Anixa Biosciences by 14.5% during the 3rd quarter. Prosperity Wealth Management Inc. now owns 41,800 shares of the company’s stock worth $138,000 after buying an additional 5,300 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Anixa Biosciences by 2.1% during the 4th quarter. Geode Capital Management LLC now owns 350,915 shares of the company’s stock worth $1,095,000 after buying an additional 7,271 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its position in shares of Anixa Biosciences by 2,000.0% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 10,500 shares of the company’s stock valued at $35,000 after buying an additional 10,000 shares during the period. Finally, NewEdge Advisors LLC acquired a new position in Anixa Biosciences in the second quarter valued at approximately $33,000. 29.13% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have weighed in on ANIX. Citigroup restated a “buy” rating on shares of Anixa Biosciences in a report on Friday, June 12th. HC Wainwright reiterated a “buy” rating on shares of Anixa Biosciences in a research report on Friday, June 12th. D. Boral Capital reissued a “buy” rating and issued a $10.00 price target on shares of Anixa Biosciences in a research note on Tuesday, June 30th. Zacks Research lowered shares of Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 19th. Finally, Wall Street Zen raised shares of Anixa Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, June 20th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Anixa Biosciences presently has an average rating of “Hold” and an average target price of $8.50.

About Anixa Biosciences

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.